vorinostat has been researched along with Waldenstrom Macroglobulinemia in 3 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Waldenstrom Macroglobulinemia: A lymphoproliferative disorder characterized by pleomorphic B-LYMPHOCYTES including PLASMA CELLS, with increased levels of monoclonal serum IMMUNOGLOBULIN M. There is lymphoplasmacytic cells infiltration into bone marrow and often other tissues, also known as lymphoplasmacytic lymphoma. Clinical features include ANEMIA; HEMORRHAGES; and hyperviscosity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sun, JY | 1 |
| Tseng, H | 1 |
| Xu, L | 1 |
| Hunter, Z | 1 |
| Ciccarelli, B | 1 |
| Fulciniti, M | 1 |
| Zhu, B | 1 |
| Maghsoudi, K | 1 |
| Yang, G | 1 |
| Gong, P | 1 |
| Zhou, Y | 1 |
| Liu, X | 1 |
| Munshi, NC | 2 |
| Patterson, CJ | 1 |
| Treon, SP | 1 |
| Grant, S | 1 |
| Mitsiades, N | 1 |
| Mitsiades, CS | 1 |
| Richardson, PG | 1 |
| McMullan, C | 1 |
| Poulaki, V | 1 |
| Fanourakis, G | 1 |
| Schlossman, R | 1 |
| Chauhan, D | 1 |
| Hideshima, T | 1 |
| Richon, VM | 1 |
| Marks, PA | 1 |
| Anderson, KC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| IGHID 11424 - A Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection (The VOR VAX Study)[NCT02707900] | Phase 1 | 6 participants (Actual) | Interventional | 2016-03-31 | Terminated (stopped due to Manufacturing of the AGS-004 HIV vaccine by Argos could no longer be provided.) | ||
| A Phase I/II Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma[NCT01297764] | Phase 1/Phase 2 | 17 participants (Actual) | Interventional | 2011-04-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 other studies available for vorinostat and Waldenstrom Macroglobulinemia
| Article | Year |
|---|---|
Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells.
Topics: Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Line; Enzyme Activation; Extracellular Signal-R | 2011 |
Targeting Waldenstrom macroglobulinemia with histone deacetylase inhibitors.
Topics: Apoptosis; Extracellular Signal-Regulated MAP Kinases; Histone Deacetylase Inhibitors; Humans; Hydro | 2011 |
Molecular sequelae of histone deacetylase inhibition in human malignant B cells.
Topics: Acetylation; Apoptosis; B-Lymphocytes; Bone Marrow Cells; Cysteine Proteinase Inhibitors; Enzyme Inh | 2003 |
Molecular sequelae of histone deacetylase inhibition in human malignant B cells.
Topics: Acetylation; Apoptosis; B-Lymphocytes; Bone Marrow Cells; Cysteine Proteinase Inhibitors; Enzyme Inh | 2003 |
Molecular sequelae of histone deacetylase inhibition in human malignant B cells.
Topics: Acetylation; Apoptosis; B-Lymphocytes; Bone Marrow Cells; Cysteine Proteinase Inhibitors; Enzyme Inh | 2003 |
Molecular sequelae of histone deacetylase inhibition in human malignant B cells.
Topics: Acetylation; Apoptosis; B-Lymphocytes; Bone Marrow Cells; Cysteine Proteinase Inhibitors; Enzyme Inh | 2003 |